Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Having signed informed consent; * Histological or clinical diagnosis of hepatocellular carcinoma（HCC）; * The target lesion should had at least one diameter line available for measurement, with the maximum diameter ≥5cm and ≤10cm； * Barcelona Clinic Liver Cancer staging B or C; * Child-Pugh liver function class: score≤7； * Eastern Cooperative Oncology Group performance 0 or 1; * At least 12 weeks life expectancy; * Never received systemic treatment, such as oral molecularly targeted drugs and systemic chemotherapy; * Be able to abide by the treatment and follow-up plan； * Adequate results for laboratory tests, including: 1. Neutrophil count≥1.5×109/L, platelet count≥60×109 /L; hemoglobin≥85g/L; 2. Total bilirubin≤51.3 μmol/L, albumin≥28 g/L,and alanine aminotransferase and aspartate aminotransferase≤5 times the upper limit of the normal range; 3. Amylase and lipase≤1.5 times the upper limit of the normal range 4. Serum creatinine≤20 g/L 5. Prothrombin time international normalized ratio ≤1.7; or prothrombin time≤4seconds above control; 6. Left ventricular ejection fraction≥50% according to two-dimensional echocardiography; * Contraception: during the trail and 12 weeks after the withdrawal, female of childbearing age (WOCBP), WOCBP whose male partners receive study drug or male must use appropriate contraceptive to avoid pregnancy; Exclusion Criteria: * Disease should be excluded: 1. CT / MRI showed diffuse lesions; 2. Extrahepatic metastasis (metastasis in lungs not included); 3. Invasion in the main portal vein / vena cava or other major vascular; 4. Previous shunt surgery; 5. PreviousTACE or transarterial embolization for HCC, unless there is a untreated lesion; 6. Hepatic encephalopathy in the past or present; 7. Current ascites requiring treatment; * Medical history and concomitant diseases: 1. Previous or current cancer other than HCC, unless it is cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1). Cancer having received curative treatment 5 years ago will not be excluded; 2. Disease history in the cardiovascular system as the following: (a)Uncontrolled hypertension；(b)Congestive heart failure in New York Heart Association grade 3 or 4; (c)Active coronary artery disease within 12 months, unstable angina or newly diagnosed angina/myocardial infarction;(d)Arrhythmia requiring drugs other than β-blockers and digoxin;(e)Valvular heart disease ≥ CTCAE grade 2； c) Corrected QT interval (Fridericia)\> 450 ms confirmed by 2 ECGs in a row d) Thrombotic or embolic events within 6 months, e) Gastrointestinal bleeding within 6 months; f) Unstable and / or active stomach ulcer within 6 months, unless gastroscopy showed it to be fully recovered; g) Variceal bleeding within 6 months; h) Unhealed wound or ulcer, fracture within 3 months; i) Major surgery, open biopsy, or severe trauma within 3 weeks; j) History of organ transplant or subjects in the transplant waiting list; k) Uncontrolled abnormal thyroid function; l) HIV infection; m) Active or untreated hepatitis B; * laboratory tests unsuitable for the enrollment： 1. Hyponatremia, serum sodium \<130 mmol / L； 2. Hypokalemia, serum potassium \<3.5 mmol / L； * Allergic reactions to arsenic trioxide and any other drugs used in this trail; * Forbidden therapies and/or drugs: 1. Condensation treatment (e.g., warfarin or heparin); 2. Chronic antiplatelet therapy (Aspirin ≥ 300 mg / day; clopidogrel ≥ 75 mg / day); 3. Radiotherapy within 4 weeks;